Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838277 | 1.00 | GRM5 (0.55) | GRM5L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3838292 | 0.89 | GRM5 (0.59) | GRM5L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3838293 | 0.89 | GRM5 (0.59) | GRM5L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3284072 | 0.88 | GRM5 (0.57) | GRM5L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL990125 | 0.88 | GRM5 (0.57) | GRM5L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3800762 | 0.82 | GRM5 (0.52) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL3713489 | 0.82 | GRM5 (0.52) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL3836423 | 0.80 | GRM5 (0.58) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL3836422 | 0.80 | GRM5 (0.58) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL3837282 | 0.80 | GRM5 (0.58) | GRM5L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877367-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | claimed |
| US-20080194551-A1 | Acetylene Derivatives | NOVARTIS PHARMA GMBH (AT) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194551-A1 | Acetylene Derivatives | NAT1, B3GNT2, NAT10 | GRM5 3731/4885L3MBTL1 4529/4885NPC1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.